Table 1A. Visual and anatomical outcomes after converting to aflibercept in the study population with refractory neovascular age-related macular degeneration (n=21).
| Parameter | Baseline mean±SD (range) | 1 Month mean±SD (range) | 3 Months mean±SD (range) | 6 Months mean±SD (range) | 12 Months mean±SD (range) | P-valuea |
|---|---|---|---|---|---|---|
| BCVA (logMAR) | 0.42±28 (0.1–0.90) | 0.39±0.30 (0–1) | 0.39±0.31 (0–1) | 0.42±0.28 (0–0.83) | 0.40±0.28 (0–1) | 0.48 |
| Central subfoveal thickness (μm) | 329.38±102.67 (216–637) | 306.05±92.62 (200–608) | 332.14±101.70 (208–658) | 304.14±83.48 (206–609) | 294.7±91.35 (193–627) | 0.038 |
| Macular volume (mm3) | 7.71±1.32 (4.83–10.15) | 7.40±1.15 (4.71–8.60) | 7.75±1.27 (4.92–9.32) | 7.52±1.13 (5.23–9.02) | 7.33±1.27 (5.07–9.36) | 0.033 |
Abbreviations: BCVA, best-corrected visual acuity; logMAR, logarithm of minimal angle of resolution; PED, pigment epithelial detachment.
a
Paired t-test, baseline compared with 12 months follow-up.